Scilex Holding (SCLX) Long-Term Investments (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Long-Term Investments of $4.8 million for Q1 2026, down 93.89% year-over-year from $79.1 million in Q1 2025, and down 96.97% quarter-over-quarter from $159.4 million in Q4 2025.
Scilex Holding (SCLX) Long-Term Investments (2021 - 2026) Analysis & Trends
Scilex Holding's Long-Term Investments history runs 5 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 93.89% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 93.89% YoY), while the FY2025 annual figure was $159.4 million, up 6486.9% from the prior year.
- Long-Term Investments for Q1 2026 stood at $4.8 million, down from $159.4 million in the prior quarter.
- The five-year high for Long-Term Investments was $159.4 million in Q4 2025, with the low at $2.4 million in Q3 2024.
- The 4-year median for Long-Term Investments is $47.7 million (2025), against an average of $65.0 million.
- The sharpest annual moves came in 2025 and 2026: Long-Term Investments surged 6486.9% in 2025, then slumped 93.89% in 2026.
- Scilex Holding's Long-Term Investments stood at $101.3 million in 2022, then tumbled by 97.61% to $2.4 million in 2024, then soared by 6486.9% to $159.4 million in 2025, then slumped by 96.97% to $4.8 million in 2026.
- Business Quant data shows SCLX's Long-Term Investments at $4.8 million in Q1 2026, $159.4 million in Q4 2025, and $16.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 56.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.83 Mn |
| Dec 31, 2025 | 159.40 Mn |
| Sep 30, 2025 | 16.35 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 79.10 Mn |
| Dec 31, 2024 | 2.42 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 141.59 Mn |
| Mar 31, 2022 | 140.45 Mn |
| Dec 31, 2021 | 139.41 Mn |
| Sep 30, 2021 | 139.41 Mn |
| Jun 30, 2021 | 139.41 Mn |
| Mar 31, 2021 | 139.40 Mn |